GlassScriptPhysician profile
Joseph A Pion
NPI 1790750735
$2,725.86
in general payments reported to CMS, 2019-2025
36 companies · $550 in 2025
The $550 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $140 · 2021: $406 · 2022: $359 · 2023: $375 · 2024: $459 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $383.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $248.76 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $228.25 | 2021-2025 | |
| Pfizer INC. | $220.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $204.40 | 2019-2025 | Trelegy Ellipta, Bexsero, Penmenvy |
| Merck Sharp & Dohme LLC | $181.13 | 2019-2025 | Vaxelis, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.94 | 2019-2025 | Jardiance |
| Amgen INC. | $137.70 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $111.47 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $77.44 | 2019-2025 | Xarelto, Spravato |
| Novartis Pharmaceuticals Corporation | $73.16 | 2019-2024 | |
| Amarin Pharma, INC. | $65.47 | 2019-2021 | |
| Sanofi Pasteur INC. | $63.29 | 2020-2023 | |
| Reflow Medical INC | $43.36 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $42.48 | 2019-2025 | Eliquis |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $42.21 | 2022-2023 | Injectafer |
| Allergan, INC. | $33.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.15 | 2019-2022 | |
| Exact Sciences Corporation | $29.62 | 2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $28.96 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $28.86 | 2021-2022 | |
| Abbott Laboratories | $24.91 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $24.21 | 2024 | Veozah |
| Mylan Specialty L.P. | $22.70 | 2019 | |
| Ibsa Pharma INC. | $22.24 | 2024 | Tirosint, Licart |
| Biohaven Pharmaceuticals, INC. | $21.78 | 2021 | |
| Lundbeck LLC | $21.14 | 2024 | Rexulti |
| Dexcom, INC. | $20.72 | 2023 | Dexcom G6 Transmitter |
| Radius Health, INC. | $20.51 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.76 | 2025 | Keveyis |
| Philips North America LLC | $16.67 | 2025 | Vest Therapy Und |
| Cequr Corporation | $16.02 | 2025 | Cequr Simplicity |
| Alexion Pharmaceuticals, INC. | $15.44 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.56 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $12.00 | 2021 | |
| Bardy Diagnostics, INC. | $4.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Pion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.